TELA Bio, Inc. (NASDAQ:TELA) Insider Ew Healthcare Partners Fund 2, Acquires 5,000 Shares

TELA Bio, Inc. (NASDAQ:TELAGet Rating) insider Ew Healthcare Partners Fund 2, purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 27th. The shares were bought at an average price of $9.05 per share, with a total value of $45,250.00. Following the completion of the acquisition, the insider now owns 3,345,709 shares of the company’s stock, valued at approximately $30,278,666.45. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ew Healthcare Partners Fund 2, also recently made the following trade(s):

  • On Friday, April 29th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were bought at an average price of $9.17 per share, with a total value of $45,850.00.
  • On Monday, April 25th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $9.49 per share, for a total transaction of $47,450.00.
  • On Monday, April 18th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $9.80 per share, for a total transaction of $49,000.00.
  • On Thursday, April 14th, Ew Healthcare Partners Fund 2, acquired 589 shares of TELA Bio stock. The shares were acquired at an average cost of $10.00 per share, for a total transaction of $5,890.00.
  • On Thursday, March 31st, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The stock was purchased at an average cost of $11.54 per share, for a total transaction of $57,700.00.
  • On Tuesday, March 29th, Ew Healthcare Partners Fund 2, purchased 3,052 shares of TELA Bio stock. The stock was purchased at an average cost of $11.65 per share, for a total transaction of $35,555.80.
  • On Tuesday, March 22nd, Ew Healthcare Partners Fund 2, purchased 136 shares of TELA Bio stock. The stock was purchased at an average cost of $11.65 per share, for a total transaction of $1,584.40.
  • On Wednesday, March 16th, Ew Healthcare Partners Fund 2, bought 2,331 shares of TELA Bio stock. The shares were bought at an average cost of $11.65 per share, for a total transaction of $27,156.15.
  • On Monday, March 14th, Ew Healthcare Partners Fund 2, bought 3,473 shares of TELA Bio stock. The shares were bought at an average cost of $11.68 per share, for a total transaction of $40,564.64.
  • On Thursday, February 24th, Ew Healthcare Partners Fund 2, purchased 5,572 shares of TELA Bio stock. The shares were acquired at an average price of $11.74 per share, for a total transaction of $65,415.28.

Shares of NASDAQ TELA opened at $9.26 on Friday. The firm’s 50-day simple moving average is $11.31 and its 200 day simple moving average is $12.04. The company has a market cap of $134.75 million, a price-to-earnings ratio of -4.04 and a beta of 1.50. The company has a quick ratio of 4.86, a current ratio of 5.58 and a debt-to-equity ratio of 1.57. TELA Bio, Inc. has a 12-month low of $8.82 and a 12-month high of $16.53.

TELA Bio (NASDAQ:TELAGet Rating) last issued its quarterly earnings results on Monday, March 21st. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.05). The company had revenue of $8.37 million for the quarter, compared to analyst estimates of $7.90 million. TELA Bio had a negative return on equity of 106.93% and a negative net margin of 112.94%. During the same quarter last year, the company earned ($0.54) EPS. On average, equities analysts expect that TELA Bio, Inc. will post -1.86 earnings per share for the current year.

A number of equities research analysts have weighed in on TELA shares. JMP Securities reiterated a “buy” rating and set a $22.00 price target on shares of TELA Bio in a research note on Tuesday, March 22nd. Zacks Investment Research upgraded shares of TELA Bio from a “sell” rating to a “hold” rating in a research note on Tuesday, April 12th.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. raised its holdings in TELA Bio by 4.1% during the 4th quarter. BlackRock Inc. now owns 22,392 shares of the company’s stock worth $287,000 after purchasing an additional 886 shares during the last quarter. Susquehanna International Group LLP bought a new stake in shares of TELA Bio in the 4th quarter valued at about $254,000. Opaleye Management Inc. increased its stake in shares of TELA Bio by 1.5% in the 4th quarter. Opaleye Management Inc. now owns 449,867 shares of the company’s stock valued at $5,758,000 after acquiring an additional 6,668 shares during the last quarter. Essex Woodlands Management Inc. increased its stake in shares of TELA Bio by 3.9% in the 4th quarter. Essex Woodlands Management Inc. now owns 1,906,228 shares of the company’s stock valued at $24,400,000 after acquiring an additional 72,239 shares during the last quarter. Finally, Pentwater Capital Management LP increased its stake in shares of TELA Bio by 0.3% in the 4th quarter. Pentwater Capital Management LP now owns 312,238 shares of the company’s stock valued at $3,997,000 after acquiring an additional 1,022 shares during the last quarter. 87.74% of the stock is owned by hedge funds and other institutional investors.

TELA Bio Company Profile (Get Rating)

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

See Also

Insider Buying and Selling by Quarter for TELA Bio (NASDAQ:TELA)

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.